Skip to main navigation Skip to search Skip to main content

Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication

  • Lukas Schuierer
  • , Michael Gebhard
  • , Hans Georg Ruf
  • , Ulrich Jaschinski
  • , Thomas M. Berghaus
  • , Michael Wittmann
  • , Georg Braun
  • , Dirk H. Busch
  • , Reinhard Hoffmann
  • Technical University of Munich
  • University Hospital Augsburg
  • University Hospital Augsburg

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Background: Herpes simplex virus (HSV) replication can be detected in the respiratory secretions of a high proportion of ventilated intensive care unit (ICU) patients. However, the clinical significance remains poorly defined. We investigated whether patients with ventilator-associated pneumonia not responding to antibiotics and in whom high levels of HSV could be detected in respiratory secretions benefit from acyclovir treatment. Methods: Respiratory secretions (bronchoalveolar lavage fluid or tracheal aspirates) were tested for HSV replication by quantitative real-time PCR. ICU survival times, clinical parameters, and radiographic findings were retrospectively compared between untreated and acyclovir treated patients with high (> 105 HSV copies/mL) and low (103-105 HSV copies/mL) viral load. Results: Fifty-seven low and 69 high viral load patients were identified. Fewer patients with high viral load responded to antibiotic treatment (12% compared to 40% of low load patients, p = 0.001). Acyclovir improved median ICU survival (8 vs 22 days, p = 0.014) and was associated with a significantly reduced hazard ratio for ICU death (HR = 0.31, 95% CI 0.11-0.92, p = 0.035) in high load patients only. Moreover, circulatory and pulmonary oxygenation function of high load patients improved significantly over the course of acyclovir treatment: mean norepinephrine doses decreased from 0.05 to 0.02 μg/kg body weight/min between days 0 and 6 of treatment (p = 0.049), and median PaO2/FiO2 ratio increased from 187 to 241 between day 3 and day 7 of treatment (p = 0.02). Chest radiographic findings also improved significantly (p < 0.001). Conclusions: In patients with ventilator-associated pneumonia, antibiotic treatment failure, and high levels of HSV replication, acyclovir treatment was associated with a significantly longer time to death in the ICU and improved circulatory and pulmonary function. This suggests a causative role for HSV in this highly selected group of patients.

Original languageEnglish
Article number12
JournalCritical Care
Volume24
Issue number1
DOIs
StatePublished - 10 Jan 2020

Keywords

  • Acyclovir
  • Bronchoalveolar lavage fluid
  • Real-time polymerase chain reaction
  • Simplexvirus
  • Ventilator-associated pneumonia

Fingerprint

Dive into the research topics of 'Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication'. Together they form a unique fingerprint.

Cite this